Charm Therapeutics is a clinical-stage biotechnology company headquartered in London, United Kingdom, that sits at the intersection of deep learning and structural biology. Founded in 2021 by Laksh Aithani and world-renowned protein scientist David Baker, the company is dedicated to transforming the drug discovery process for complex, previously "undruggable" disease targets. The companyâ??s mission is centered on the belief that better structural insights lead to better medicines, and they achieve this by utilizing proprietary artificial intelligence architectures to predict how small molecules interact with proteins.
While traditional drug discovery often relies on labor-intensive physical screening and iterative medicinal chemistry, Charm Therapeutics utilizes a "computational-first" approach. By predicting the co-complex structure of a protein and a ligand simultaneously, the company aims to significantly reduce the time and cost associated with bringing high-affinity drug candidates to the clinic, particularly in the fields of oncology and other high-unmet-need therapeutic areas.
Core Technology: DragonFold
The technological backbone of Charm Therapeutics is a proprietary deep learning platform known as DragonFold. This platform represents a significant leap beyond previous iterations of structural biology AI, such as AlphaFold, which primarily focused on predicting the 3D shape of proteins in isolation.
End-to-End Co-folding
DragonFold is an end-to-end 3D deep learning algorithm designed for "protein-ligand co-folding." Unlike traditional "docking" methodsâ??where a small molecule is computationally placed into a static protein structureâ??DragonFold predicts the structure of the protein and the small molecule together in a single step. This allows the model to account for the "induced fit" phenomenon, where a protein changes its shape to accommodate the binding of a drug molecule.
Atomic Precision
The platform functions at atomic resolution, allowing scientists to visualize the specific interactions (such as hydrogen bonding, van der Waals forces, and hydrophobic effects) that govern binding affinity and selectivity. This precision allows Charm to design molecules that fit into difficult-to-target pockets on a proteinâ??s surface, which were previously considered invisible or inaccessible to conventional screening methods.
Data-Driven Refinement
The DragonFold engine is trained on massive datasets of experimental protein-ligand structures. It continuously improves as new experimental data is integrated, creating a feedback loop between the company's computational predictions and its wet-lab validation results.
Products and Pipeline Development
Charm Therapeutics does not operate as a traditional service provider or Contract Research Organization (CRO). Instead, it functions as a therapeutic discovery company that uses its platform to build an internal pipeline of proprietary drug candidates.
Small Molecule Discovery
The primary "product" of the DragonFold platform is the identification of high-quality chemical leads. The company focuses on small molecules, which offer several advantages over biologics, including oral bioavailability and the ability to penetrate cell membranes to reach intracellular targets.
Target Selection
Charm focuses on high-value targets in oncology. Many of these targets are proteins that are known to drive cancer progression but have been historically difficult to inhibit because they lack deep, well-defined binding pockets. By using DragonFold to discover "cryptic" or transient pockets, Charm is developing first-in-class inhibitors for these challenging proteins.
Pipeline Stage
The company is currently in the discovery and preclinical development phase. While specific drug candidate names are often kept confidential for competitive reasons during early development, the pipeline is geared toward the following:
1. First-in-class oncology therapeutics targeting transcriptions factors and protein-protein interactions.
2. Best-in-class molecules designed to overcome resistance mechanisms in existing cancer treatments.
Services and Collaborative Research
While the internal pipeline is the company's primary focus, Charm Therapeutics engages with the broader scientific community and potential partners through strategic collaborations:
Strategic Partnerships
Charm leverages its DragonFold platform to form partnerships with larger pharmaceutical entities. In these arrangements, Charm provides the computational structural biology expertise and lead discovery capabilities, while the partner may provide therapeutic area expertise and clinical development infrastructure. These collaborations help validate the platform across diverse target classes beyond the companyâ??s core focus.
Experimental Validation
To support its computational outputs, Charm operates state-of-the-art laboratory facilities in London. These labs provide the following internal services:
- Protein Expression and Purification: Creating the target proteins for experimental testing.
- X-ray Crystallography and Cryo-EM: Obtaining physical images of protein-ligand complexes to verify the accuracy of DragonFold's predictions.
- Biochemical and Cellular Assays: Testing the biological activity of the predicted drug candidates in living cells to ensure they have the desired therapeutic effect.
Scientific Foundation and Leadership
The credibility of Charm Therapeutics is rooted in its founding team. Laksh Aithani, CEO, previously served as a Machine Learning Engineer at Exscientia and was an Entrepreneur-in-Residence at Lux Capital. Co-founder David Baker is a pioneer in protein design, a professor at the University of Washington, and the recipient of the 2024 Nobel Prize in Chemistry (for his work on computational protein design).
The company is backed by a prestigious group of investors, including F-Prime Capital, OrbiMed, Fujifilm Capital, Khosla Ventures, and NVIDIA. This backing has allowed the company to scale its computational infrastructure and recruit a multidisciplinary team of deep learning researchers, structural biologists, and medicinal chemists.
Impact on the Biotech Ecosystem
Charm Therapeutics represents a shift in the United Kingdomâ??s biotech landscape, moving toward "TechBio"â??a sector where technology and software engineering are as fundamental to the business as biology. By successfully applying 3D deep learning to the most difficult problems in molecular recognition, Charm is positioning itself as a leader in the next generation of drug discovery, where the "undruggable" becomes "druggable" through the power of predictive modeling.
